Progyny (NASDAQ:PGNY) Sets New 1-Year Low – Here’s What Happened

Shares of Progyny, Inc. (NASDAQ:PGNY) hit a new 52-week low during trading on Friday . The company traded as low as $16.75 and last traded at $17.6240, with a volume of 2169972 shares traded. The stock had previously closed at $22.25.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS $0.48 vs. $0.38 est.; revenue $318.4M vs. ~$314M est.), showing year-over-year revenue growth. Read More.
• Positive Sentiment: Strong cash generation and shareholder returns: Progyny reported record $210.2M operating cash flow for the year and has repurchased ~6.5M shares under its authorization to date. Read More.
• Positive Sentiment: FY 2026 EPS guidance was raised above consensus (1.83–1.95 vs. ~1.55Street est.), indicating management expects better full‑year profitability despite near‑term revenue headwinds. Read More.
• Neutral Sentiment: Transcripts and slide deck from the earnings call are available for investors who want management detail on drivers (retention, pricing, membership growth) and cadence of benefits. Read More.
• Negative Sentiment: Near‑term revenue guidance disappointed: Q1 2026 revenue guidance ($319M–$332M) is below consensus (~$345M), which likely explains the sell‑off despite the EPS beat and stronger FY EPS outlook. Read More.
• Negative Sentiment: Short interest has risen materially (reported ~41% increase in shares sold short in February to ~4.0M shares, ~5.1% of float), increasing downside pressure and volatility. Read More.

Analyst Ratings Changes

PGNY has been the subject of several research analyst reports. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Citizens Jmp upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective on the stock in a report on Tuesday, January 20th. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a report on Wednesday, January 21st. Truist Financial raised Progyny from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Thursday, January 8th. Finally, Citigroup upgraded Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.80.

Progyny Stock Down 20.5%

The firm has a market capitalization of $1.53 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 1.12 and a beta of 0.96. The company’s 50-day simple moving average is $23.90 and its 200 day simple moving average is $23.11.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.38%. The firm had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter in the previous year, the business posted $0.42 EPS. Progyny’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Institutional Trading of Progyny

Institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. boosted its stake in Progyny by 57.1% in the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after purchasing an additional 256,078 shares in the last quarter. Cresset Asset Management LLC raised its holdings in shares of Progyny by 715.3% in the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company’s stock worth $1,871,000 after buying an additional 74,621 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Progyny during the second quarter worth $327,000. Y Intercept Hong Kong Ltd lifted its stake in shares of Progyny by 88.0% during the second quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock worth $1,236,000 after buying an additional 26,310 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Progyny by 33.1% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock valued at $35,649,000 after buying an additional 412,395 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.